A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor.

@article{Chang2005ASO,
  title={A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor.},
  author={Lisa C W Chang and Jacobien K. von Frijtag Drabbe K{\"u}nzel and Thea Mulder-Krieger and Ronald F Spanjersberg and Sophie F. Roerink and Gijs van den Hout and Margot W. Beukers and Johannes Brussee and Adriaan P. IJzerman},
  journal={Journal of medicinal chemistry},
  year={2005},
  volume={48 6},
  pages={
          2045-53
        }
}
Adenosine receptor agonists are usually variations of the natural ligand, adenosine. The ribose moiety in the ligand has previously been shown to be of great importance for the agonistic effects of the compound. In this paper, we present a series of nonadenosine ligands selective for the adenosine A(1) receptor with an extraordinary pharmacological profile. 2-Amino-4-benzo[1,3]dioxol-5-yl-6-(2-hydroxyethylsulfanyl)pyridine-3,5-dicarbonitrile (70, LUF 5853) shows full agonistic behavior… 
View on PubMed
doi.org
95 Citations
Highly Influential Citations
1
Background Citations
16
Methods Citations
3

95 Citations

Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.
TLDR
Among the antagonists described above, compound OT-7999 is expected to enter clinical trials for the treatment of glaucoma, while several thiazole derivatives are in development as antiallergic, antiasthmatic and/or antiinflammatory drugs.
A Novel Nonribose Agonist, LUF5834, Engages Residues That Are Distinct from Those of Adenosine-Like Ligands to Activate the Adenosine A2a Receptor
TLDR
The findings suggest that this class of agonist interacts with distinct residues to activate the receptor compared with classic adenosine derived agonists.
Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: insight into the receptor activation switch.
A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines.
A3 Adenosine Receptor Agonists: History and Future Perspectives
TLDR
The potency and efficacy of various adenosine derivatives at the A3AR also depends on the second messenger system being studied, which has led to a proposed concept of “effect reversal” for this receptor.
Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors. Ranging from Pan Ligands to Combined A1/A2B Partial Agonists
TLDR
The present SAR study has helped to confirm the 1H-imidazol-2-yl group at R2 position as an important feature for producing potent AR agonists and the nature of the R1 substituent highly affects not only affinity/activity at the hA1 and hA2B ARs but also selectivity versus the other subtypes.
Modifications on the amino-3,5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity.
TLDR
A new series of amino-3,5-dicyanopyridines was synthesized and biologically evaluated in order to further investigate the potential of this scaffold to obtain adenosine receptor (AR) ligands and showed to reduce oxaliplatin-induced neuropathic pain.
Agonists for the adenosine A1 receptor with tunable residence time. A Case for nonribose 4-amino-6-aryl-5-cyano-2-thiopyrimidines.
TLDR
The synthesis and evaluation of previously unreported 4-amino-6-aryl-5-cyano-2-thiopyrimidines as selective human adenosine A1 receptor agonists with tunable binding kinetics are reported, bringing new evidence of the consequences of affinity-only driven selection of drug candidates.
Structure‐affinity relationships of adenosine A2B receptor ligands
TLDR
This review presents an overview of the structure‐affinity relationships of antagonists and agonists for this receptor subtype as published in the scientific and patent literature.
Design and Pharmacological Profile of a Novel Covalent Partial Agonist for the Adenosine A1 Receptor.
...
...